The effect of water-soluble pristine C60 fullerene on 6-OHDA-induced Parkinson’s disease in rats

V. O.  Stetska; T. V.  Dovbynchuk; Y. S.  Makedon; N. V.  Dziubenko

doi:10.15421/022182

V. O. Stetska Taras Shevchenko National University of Kyiv
T. V. Dovbynchuk Taras Shevchenko National University of Kyiv
Y. S. Makedon Taras Shevchenko National University of Kyiv
N. V. Dziubenko Taras Shevchenko National University of Kyiv

Keywords: motility; non-motor symptoms; antioxidant system; gastrointestinal transit time

Abstract

Oxidative stress is thought to be one of the mechanisms that leads to the dysfunction and degeneration of dopaminergic neurons in Parkinson’s disease pathogenesis and presumed to be underway during the prodromal phase. Therefore, therapy, which is effective against pre-motor symptoms, might be effective in preventing or delaying the development and progression of Parkinson’s disease. The aim of our study was to investigate the therapeutic efficiency of pristine C60 fullerene aqueous solution (C60FAS) during Parkinson’s disease in rats. The unilateral dopamine deficiency was induced in male Wistar rats (220–250 g) by stereotaxic microinjection of neurotoxin 6-hydroxydopamine (6-OHDA, 12 μg). C60FAS was injected to rats intraperitoneally daily for 10 days (0.65 mg/kg per day). The percentage of destroyed dopaminergic neurons was determined by the apomorphine test and by IHC staining of tyrosine hydroxylase-positive neurons in substantia nigra. We evaluated the rat body weight, the water and food intake, Open Field behavioural test, the level of biochemical antioxidant system, the activity of peritoneal macrophages. Levels of spontaneous and carbachol-stimulated colon motility were estimated by ballonographic method in vivo. C60FAS showed a positive tendency to increase the number of tyrosine hydroxylase-positive cells in the midbrain, which was associated with more profound improvement in apomorphine-rotation behaviour and slight relief of the anxiety level in Open Field test. Furthermore, C60FAS treatment increased the index of stimulated distal colon motor activity while it did not have a significant effect on water content in feces and total gastrointestinal transit time. C60FAS treatment did not affect water intake behaviour or body weight changes while it induced an increase of glutathione level and decrease activity of glutathione peroxidase in the brain as well as an increase in activity of peritoneal macrophages in 6-OHDA-Parkinson’s disease rats. These findings confirmed the potential therapeutic effectiveness of water-soluble pristine C60 fullerene in Parkinson’s disease pathogenesis, though there is ground for caution because of its systemic mild toxic effect.

References

Aillon, K. L., Xie, Y., El-Gendy, N., Berkland, C. J., & Forrest, M. L. (2009). Effects of nanomaterial physicochemical properties on in vivo toxicity. Advanced Drug Delivery Reviews, 61, 457–466.

Amani, H., Habibey, R., Hajmiresmail, S. J., Latifi, S., Pazoki-Toroudi, H., & Akhavan, O. (2017). Antioxidant nanomaterials in advanced diagnoses and treatments of ischemia reperfusion injuries. Journal of Materials Chemistry B, 48, 9452–9476.

Ambani, L. M., Van Woert, M. H., & Murphy, S. (1975). Brain peroxidase and catalase in Parkinson disease. Archives of Neurology, 32(2), 114–118.

Baldrighi, M., Trusel, M., Tonini, R., & Giordani, S. (2016). Carbon nanomaterials interfacing with neurons: An in vivo perspective. Frontiers in Neuroscience, 10, 1–27.

Bharath, S., Hsu, M., Kaur, D., Rajagopalan, S., & Andersen, J. K. (2002). Glutathione, iron and Parkinson’s disease. Biochemical Pharmacology, 64(5–6), 1037–1048.

Braak, H., Del Tredici, K., Rüb, U., De Vos, R. A. I., Jansen Steur, E. N. H., & Braak, E. (2003). Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiology of Aging, 24(2), 197–211.

Cai, X., Jia, H., Liu, Z., Hou, B., Luo, C., Feng, Z., Wenxin, L., & Liu, J. (2008). Polyhydroxylated fullerene derivative C60(OH)24 prevents mitochondrial dysfunction and oxidative damage in an MPP+-induced cellular model of Parkinson’s disease. Journal of Neuroscience Research, 86(16), 3622–3634.

Chen, H., Zhang, S. M., Herna, M. A., Willett, W. C., & Ascherio, A. (2003). Weight loss in Parkinson’s disease. Annals of Neurology, 53(5), 676–679.

Dragojevic-Simic, V., Jacevic, V., Dobric, S., Djordjevic, A., Bokonjic, D., Bajcetic, M., & Injac, R. (2011). Anti-inflammatory activity of fullerenol C60(OH)24 nano-particles in a model of acute inflammation in rats. Digest Journal of Nanomaterials and Biostructures, 6(2), 819–827.

Dringen, R., Gutterer, J. M., & Hirrlinger, J. (2000). Glutathione metabolism in brain: Metabolic interaction between astrocytes and neurons in the defense against reactive oxygen species. European Journal of Biochemistry, 267, 4912–4916.

Dugan, L. L., Lovett, E. G., Quick, K. L., Lotharius, J., Lin, T. T., & O’Malley, K. L. (2001). Fullerene-based antioxidants and neurodegenerative disorders. Parkinsonism and Related Disorders, 7(3), 243–246.

Dugan, Laura L., Tian, L. L., Quick, K. L., Hardt, J. I., Karimi, M., Brown, C., Loftin, S., Flores, H., Moerlein, S., Polich, J., Tabbal, S. D., Mink, & Perlmutter, J. S. (2014). Carboxyfullerene neuroprotection postinjury in parkinsonian nonhuman primates. Annals of Neurology, 76(3), 393–402.

Ellman, G. L. (1959). Tissue sulfhydryl groups. Archives of Biochemistry and Biophysics, 82(1), 70–77.

Emelyantsev, S., Prazdnova, E., Chistyakov, V., & Alperovich, I. (2019). Biological effects of C60 fullerene revealed with bacterial biosensor-toxic or rather antioxidant? Biosensors, 9(2), 81.

Eom, S. A., Kim, D. W., Shin, M. J., Ahn, E. H., Chung, S. Y., Sohn, E. J., Jo, H. S., Jeon, S. J., Kim, D. S., Kwon, H. Y., Cho, S. W., Han, K. H., Park, J., Eum, W. S., & Choi, S. Y. (2015). Protective effects of PEP-1-catalase on stress-induced cellular toxicity and MPTP-induced Parkinson’s disease. BMB Reports, 48(7), 395–400.

Eswaran, S. V. (2018). Water soluble nanocarbon materials: A panacea for all? Current Science, 114(9), 1846–1850.

Faraji, B., Kang, H. K., & Valentine, J. L. (1987). Methods compared for determining glutathione peroxidase activity in blood. Clinical Chemistry, 33(4), 539–543.

Ferreira, C. A., Ni, D., Rosenkrans, Z. T., & Cai, W. (2018). Scavenging of reactive oxygen and nitrogen species with nanomaterials. Nano Research, 11(10), 4955–4984.

Gharbi, N., Pressac, M., Hadchouel, M., Szwarc, H., & Wilson, S. R. (2005). [60] Fullerene is an in vivo powerful antioxidant with no acute or sub-acute toxicity. Nano Letters, 5(12), 2578–2585.

Gonchar, O. O., Maznychenko, A. V., Bulgakova, N. V., Vereshchaka, I. V., Tomiak, T., Ritter, U., Prylutskyy, Y. I., Mankovska, I. M., & Kostyukov, A. I. (2018). C60 fullerene prevents restraint stress-induced oxidative disorders in rat tissues: Possible involvement of the Nrf2/ARE-antioxidant pathway. Oxidative Medicine and Cellular Longevity, 2018, 2518676.

Goodarzi, S., Da Ros, T., Conde, J., Sefat, F., & Mozafari, M. (2017). Fullerene: Biomedical engineers get to revisit an old friend. Materials Today, 20(8), 460–480.

Halenova, T. I., Vareniuk, I. M., Roslova, N. M., Dzerzhynsky, M. E., Savchuk, O. M., Ostapchenko, L. I., Prylutskyy, Y. I., Ritter, U., & Scharff, P. (2016). Hepatoprotective effect of orally applied water-soluble pristine C60 fullerene against CCl4-induced acute liver injury in rats. RSC Advances, 6(102), 100046–100055.

Halenova, T., Raksha, N., Vovk, T., Savchuk, O., Ostapchenko, L., Prylutskyy, Y., Kyzuma, O., Ritter, U., & Scharff, P. (2018). Effect of C60 fullerene nanoparticles on the diet-induced obesity in rats. International Journal of Obesity, 42(12), 1987–1998.

Hendrickson, O. D., Morozova, O. V., Zherdev, A. V., Yaropolov, A. I., Klochkov, S. G., Bachurin, S. O., & Dzantiev, B. B. (2015). Study of distribution and biological effects of fullerene C60 after single and multiple intragastrical administrations to rats. Fullerenes Nanotubes and Carbon Nanostructures, 23(7), 658–668.

Kalia, L. V., & Lang, A. E. (2015). Parkinson’s disease. The Lancet, 386(9996), 896–912.

Kolosnjaj, J., Szwarc, H., & Moussa, F. (2007). Toxicity studies of fullerenes and derivatives. Advances in Experimental Medicine and Biology, 620, 168–180.

Kroto, H. W., Heath, J. R., O’Brien, S. C., Curl, R. F., & Smalley, R. E. (1985). C60: Buckminsterfullerene. Nature, 318(6042), 162–163.

Kuznietsova, H., Dziubenko, N., Hurmach, V., Chereschuk, I., Motuziuk, O., Ogloblya, O., & Prylutskyy, Y. (2020). Water-soluble pristine C60 fullerenes inhibit liver fibrotic alteration and prevent liver cirrhosis in rats. Oxidative Medicine and Cellular Longevity, 2020, 1–14.

Lu, T. Y., Kao, P. F., Lee, C. M., Huang, S. T., & Lin, C. M. (2011). C60 fullerene nanoparticle prevents β-amyloid peptide induced cytotoxicity in neuro 2A cells. Journal of Food and Drug Analysis, 19(2), 151–158.

Ma, K., Xiong, N., Shen, Y., Han, C., Liu, L., Zhang, G., Wang, L., Guo, S., Guo, X., Xia, Y., Wan, F., Huang, J., Lin, Z., & Wang, T. (2018). Weight loss and malnutrition in patients with Parkinson’s disease: Current knowledge and future prospects. Frontiers in Aging Neuroscience, 10, 1.

Mortiboys, H. J., Schaefer, J., Reichmann, H., & Jackson, S. (2007). Mitochondrial dysfunction in Parkinson’s disease – revisited. Neurologia i Neurochirurgia Polska, 41, 150–159.

Moussa, F. (2018). [60] Fullerene and derivatives for biomedical applications. In: Narayan, R. (Ed.). Nanobiomaterials: Nanostructured materials for biomedical applications. Woodhead Publishing. Pp. 113–136.

Moussa, F., Trivin, F., Céolin, R., Hadchouel, M., Sizaret, P. Y., Greugny, V., Fabre, C., Rassat, A., & Szwarc, H. (1996). Early effects of C60 administration in swiss mice: A preliminary account for in vivo C60 toxicity. Fullerene Science and Technology, 4(1), 21–29.

Nilsson, L. O., Gustafsson, A., & Mannervik, B. (2000). Redesign of substrate-selectivity determining modules of glutathione transferase A1-1 installs high catalytic efficiency with toxic alkenal products of lipid peroxidation. Proceedings of the National Academy of Sciences of the United States of America, 97(17), 9408–9412.

Park, E. J., Roh, J., Kim, Y., & Park, K. (2013). Induction of inflammatory responses by carbon fullerene (C60) in cultured RAW264.7 cells and in intraperitoneally injected mice. Toxicological Research, 26(4), 267–273.

Pedrosa Carrasco, A. J., Timmermann, L., & Pedrosa, D. J. (2018). Management of constipation in patients with Parkinson’s disease. Npj Parkinson’s Disease, 4(1), 6.

Pirtošek, Z., Bajenaru, O., Kovács, N., Milanov, I., Relja, M., & Skorvanek, M. (2020). Update on the management of Parkinson’s disease for general neurologists. Parkinson’s Disease, 2020, 9131474.

Podolski, I. Y., Podlubnaya, Z. A., Kosenko, E. A., Mugantseva, E. A., Makarova, E. G., Marsagishvili, L. G., Shpagina, M. D., Kaminsky, Y. G., Andrievsky, G. V., & Klochkov, V. K. (2007). Effects of hydrated forms of C60 fullerene on amyloid β-peptide fibrillization in vitro andperformance of the cognitive task. Journal of Nanoscience and Nanotechnology, 7(4–5), 1479–1485.

Prylutska, S. V., Burlaka, A. P., Klymenko, P. P., Grynyuk, I. I., Prylutskyy, Y. I., Schütze, C., & Ritter, U. (2011). Using water-soluble C60 fullerenes in anticancer therapy. Cancer Nanotechnology, 2(1–6), 105–110.

Prylutska, S. V., Grebinyk, A. G., Lynchak, O. V., Byelinska, I. V., Cherepanov, V. V., Tauscher, E., Matyshevska, O. P., Prylutskyy, Y. I., Rybalchenko, V. K., Ritter, U., & Frohme, M. (2019). In vitro and in vivo toxicity of pristine C60 fullerene aqueous colloid solution. Fullerenes Nanotubes and Carbon Nanostructures, 27, 715–728.

Prylutska, S., Panchuk, R., Gołuński, G., Skivka, L., Prylutskyy, Y., Hurmach, V., Skorohyd, N., Borowik, A., Woziwodzka, A., Piosik, J., Kyzyma, O., Haramus, V. M., Bulavin, L., Evstigneev, M., Buchelnikov, A., Stoika, R., Berger, W., Ritter, U., & Scharff, P. (2017). C60 fullerene enhances cisplatin anticancer activity and overcomes tumor cell drug resistance. Nano Research, 10(2), 652–671.

Ritter, U., Prylutskyy, Y. I., Evstigneev, M. P., Davidenko, N. A., Cherepanov, V. V., Senenko, A. I., Marchenko, O. A., & Naumovets, A. G. (2015). Structural features of highly stable reproducible C60 fullerene aqueous colloid solution probed by various techniques. Fullerenes Nanotubes and Carbon Nanostructures, 23(6), 530–534.

Siderowf, A., & Lang, A. E. (2012). Premotor Parkinson’s disease: Concepts and definitions. Movement Disorders, 27(5), 608–616.

Skivka, L. M., Prylutska, S. V., Rudyk, M. P., Khranovska, N. M., Opeida, I. V., Hurmach, V. V., Prylutskyy, Y. I., Suchodub, O. F., & Ritter, U. (2018). C60 fullerene and its nanocomplexes with anticancer drugs modulate circulating phagocyte functions and dramatically increase ROS generation in transformed monocytes. Cancer Nanotechnology, 9(1), 1–22.

Stocchi, F., & Torti, M. (2017). Constipation in Parkinson’s disease. International Review of Neurobiology, 134, 811–826.

Sun, F., Deng, Y., Han, X., Liu, Q., Zhang, P., Manzoor, R., & Ma, H. (2019). A secret that underlies Parkinson’s disease: The damaging cycle. Neurochemistry International, 129, 104484.

Talanov, S. A., Oleshko, N. N., Tkachenko, M. N., & Sagach, V. F. (2006). Pharmacoprotective influences on different links of the mechanism underlying 6-hydroxydopamine-induced degeneration of nigro-striatal dopaminergic neurons. Neurophysiology, 38(2), 128–133.

Tipple, T. E., & Rogers, L. K. (2012). Methods for the determination of plasma or tissue glutathione levels. Methods in Molecular Biology, 889, 315–324.

Turov, V. V., Chehun, V. F., Krupskaya, T. V., Barvinchenko, V. N., Chehun, S. V., Ugnivenko, A. P., Prylutskyy, Y. I., Scharff, P., & Ritter, U. (2010). Effect of small addition of C60 fullerenes on the hydrated properties of nanocomposites based on highly dispersed silica and DNA. Chemical Physics Letters, 496(1–3), 152–156.

Viola, A., Munari, F., Sánchez-Rodríguez, R., Scolaro, T., & Castegna, A. (2019). The metabolic signature of macrophage responses. Frontiers in Immunology, 10, 1–16.

Vorobyov, V., Kaptsov, V., Gordon, R., Makarova, E., Podolski, I., & Sengpiel, F. (2015). Neuroprotective effects of hydrated fullerene C60: Cortical and hippocampal EEG interplay in an amyloid-infused rat model of Alzheimer’s disease. Journal of Alzheimer’s Disease, 45(1), 217–233.

Walsh, S., Finn, D. P., & Dowd, E. (2011). Time-course of nigrostriatal neurodegeneration and neuroinflammation in the 6-hydroxydopamine-induced axonal and terminal lesion models of Parkinson’s disease in the rat. Neuroscience, 175, 251–261.

Wang, I. C., Tai, L. A., Lee, D. D., Kanakamma, P. P., Shen, C. K. F., Luh, T. Y., Cheng, C. H., & Hwang, K. C. (1999). C60 and water-soluble fullerene derivatives as antioxidants against radical-initiated lipid peroxidation. Journal of Medicinal Chemistry, 42(22), 4614–4620.

Williams-Gray, C. H. (2016). Parkinson’s disease key points. Medicine, 44(9), 542–546.

Yano, J. M., Yu, K., Mazmanian, S. K., Correspondence, E. Y. H., Donaldson, G. P., Shastri, G. G., Ann, P., Ma, L., Nagler, C. R., Ismagilov, R. F., Mazmanian, S. K., & Hsiao, E. Y. (2015). Indigenous bacteria from the gut microbiota regulate host serotonin biosynthesis article indigenous bacteria from the gut microbiota regulate host serotonin biosynthesis. Cell, 161, 264–276.

Ye, S., Zhou, T., Pan, D., Lai, Y., Yang, P., Chen, M., Wang, Y., Hou, Z., Ren, L., & Jiang, Y. (2016). Fullerene C60 derivatives attenuated microglia-mediated prion peptide neurotoxicity. Journal of Biomedical Nanotechnology, 12(9), 1820–1833.

Yudoh, K., Karasawa, R., Masuko, K., & Kato, T. (2009). Water-soluble fullerene (C60) inhibits the development of arthritis in the rat model of arthritis. International Journal of Nanomedicine, 4, 217–225.

Zha, Y., Yang, B., Tang, M., Chen, J., Wen, L., & Wang, M. (2012). Concentration-dependent effects of fullerenol on cultured hippocampal neuron viability. International Journal of Nanomedicine, 7, 3099–3109.

Zhang, X., Cong, H., Yu, B., & Chen, Q. (2018). Recent advances of water-soluble fullerene derivatives in biomedical applications. Mini-Reviews in Organic Chemistry, 16(1), 92–99.